Immutep Limited – American Depositary Shares (NASDAQ:IMMP)’s Trend Up, Especially After Decreased Shorts

The stock of Immutep Limited – American Depositary Shares (NASDAQ:IMMP) registered a decrease of 15.83% in short interest. IMMP’s total short interest was 86,700 shares in September as published by FINRA. Its down 15.83% from 103,000 shares, reported previously. With 34,000 shares average volume, it will take short sellers 3 days to cover their IMMP’s short positions.

The stock decreased 0.67% or $0.01 during the last trading session, reaching $1.49. About 17,182 shares traded. Immutep Limited (NASDAQ:IMMP) has declined 38.58% since September 13, 2018 and is downtrending. It has underperformed by 38.58% the S&P500.

Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company has market cap of $48.97 million. The firm develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It currently has negative earnings. The Company’s core technologies are based on the lymphocyte activation gene-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune response.

More notable recent Immutep Limited (NASDAQ:IMMP) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J’s Depression Drug, Endologix Reverse Split – Benzinga” on March 06, 2019, also Finance.Yahoo.com with their article: “The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts – Yahoo Finance” published on August 03, 2019, Globenewswire.com published: “Immutep to Present at Upcoming Industry Conferences – GlobeNewswire” on February 26, 2019. More interesting news about Immutep Limited (NASDAQ:IMMP) were released by: Globenewswire.com and their article: “Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial – GlobeNewswire” published on June 13, 2019 as well as Globenewswire.com‘s news article titled: “Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast – GlobeNewswire” with publication date: March 27, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.